05-JUL-2022 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1100 878 338 158 80 23 4 08/13/2019 289 106
            878 338 158 80 23 4      
 
    2 Y 1 Lenalidomide   405 167 79 39 12 2 08/13/2019    
        2 Lenalidomide + Daratumumab   396 165 78 37 15 4      
            801 332 157 76 27 6      
 
    3 Y 3 Continue Lenalidomide   2 2 2 0 0 0 08/13/2019    
        4 Stop Lenalidomide   3 3 2 1 0 0      
        5 Continue Lenalidomide + Dara   6 6 4 1 0 0      
        6 Stop Lenalidomide + Dara   7 7 6 4 3 0      
            18 18 14 6 3 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 2 I+R+Venetoclax 62 1 1 1 0 0 0 01/05/2022 104 31
            1 1 1 0 0 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   13 10 4 1 0 0 05/27/2021 179 64
            13 10 4 1 0 0      
 
    1 E Total Registrations   7 5 4 1 0 0 05/27/2021    
            7 5 4 1 0 0      
 
    2 E Total Registrations   3 3 3 2 1 0 05/27/2021    
            3 3 3 2 1 0      
 
No A061402-Solitary Plasmacytoma, adj sys+Zol vs Zol 0 E Total Registrations   1 0 0 0 0 0 01/27/2017    
            1 0 0 0 0 0      
 
  EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   37 10 5 1 0 0 01/08/2020 252 89
            37 10 5 1 0 0      
 
    1 E Total Registrations   19 6 3 2 0 0 01/08/2020    
            19 6 3 2 0 0      
 

05-JUL-2022 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 104 31